SYNERGY™ Stent: Addressing the Full Spectrum of Cardiovascular Disease Complexity
The SYNERGY™ Stent Clinical Program and research is studying approximately 20,000 patients in a wide variety of trials and will explore many types of patient populations. This research is designed to truly reflect the situations that interventional cardiologists experience every day in the cath lab.
Global Chief-Medical-Officer, Dr. Keith Dawkins and U.S. Chief-Medical-Officer, Dr. Craig Thompson, discuss the compelling body of clinical and real-world evidence to support the safety of the SYNERGY™ Stent.
Safety Highlighted with the SYNERGY™ Stent System in the EVOLVE 5-Year Trial Data
The EVOLVE 5-Year Data presented at EuroPCR 2016 showed the Long-term Safety with the SYNERGY™ Stent System.
SYNERGY™ Stent reported lowest rates of ST in real-world SCAAR registry
In this real-world registry1 of over 83,000 patients, the SYNERGY™ stent’s thin strut design and bioabsorbable polymer coating show a trend of lower definite stent thrombosis compared to the other bioabsorbable polymer and permanent polymer drug-eluting stents.
SYNERGY™ Low Event Rates after Early DAPT Discontinuation in Complex Patients
In a retrospective, single-center analysis of 100 extremely complex patients from Belfast, Ireland, the use of the SYNERGY™ stent allowed for early discontinuation of DAPT, without an increase in the incidence of stent thrombosis, MI and cardiac death at 12 Months.